FDA acceptance of NDA supports drug development.

1 report, 1 independent Updated Sep 15

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Andrew Robbins Food and Drug Administration

Keep exploring

Part of

Cogent Biosciences plans to submit an NDA to the FDA, with Andrew Robbins as President and CEO. All 1 developments

The entities involved

Andrew Robbins
researcher

Nothing else this week.
Food and Drug Administration
government organization in Nonthaburi, Thailand
- Kymera Therapeutics is seeking alignment from the FDA for its Phase III clinical trials.Sun 15:49
- The Food and Drug Administration is enforcing food safety standards for products sold in Nashik.Sun 12:21

Related events

Biohaven filed an update on its NDA with the SEC, while the FDA indicated that advisory committee meetings were unnecessary.Jun 7

Coverage

Newest first; wire copies grouped

Sep 15empr.com